Sign up
Healthed-White-on-Blue
profile_a69a1ed5bb12afe0ff74e8da56dc3ae0

Prof Paul Van Buynder

Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland
Prof Paul Van Buynder is a Public Health Physician and the immediate past Chairman of the Australian Immunisation Coalition. He is a Professor in the School of Medicine at Griffith University in Queensland. He has held senior public health positions in a number of Australian states, in two Canadian jurisdictions and at the Centre for Infections in the United Kingdom. He has held personal appointments on sub-committees of National Immunisation Technical Advisory Committees in three continents. He is a reviewer for over 10 journals and has over 60 refereed book chapters and articles.

More from this expert

Image_Paul-Van-Buynder0
Videos iconVideos

New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

feature-image-e1512457124620
Monographs iconMonographs

Update on Herpes Zoster

This article discusses herpes zoster, the condition and its complications as well as the benefits, risks and challenges associated with the herpes zoster vaccine.

Image_Paul-Van-Buynder0
Videos iconVideos

New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Image_Paul-Van-Buynder0

New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

By Prof Paul Van Buynder
Videos iconVideos
feature-image-e1512457124620

Update on Herpes Zoster

This article discusses herpes zoster, the condition and its complications as well as the benefits, risks and challenges associated with the herpes zoster vaccine.

By A/Prof John Litt AM, Prof Tony Cunningham AO, Prof Paul Van Buynder
Monographs iconMonographs
shutterstock_2137348775

Shingles – Why it is a serious problem and why the new vaccine is a good development

Post shingles, QOL is significantly and permanently reduced.

By Prof Paul Van Buynder
Podcasts iconPodcasts
An,African,Doctor,Holding,A,Covid,19,Vaccine,Vial,In

COVID update – Tackling booster confusion, the next wave & non-mRNA jabs

Which booster when? Is bivalent or monovalent better? Plus when non-mRNA boosters are appropriate

By Prof Paul Van Buynder
Podcasts iconPodcasts
Image_Paul-Van-Buynder0

Bivalent original/omicron pre-filled syringe for COVID-19 vaccination

In this Product Explainer, Public Health Physician Prof Paul Van Buynder explains the role of the Bivalent Original/Omicron BA.4-5 pre-filled syringe COVID-19 vaccine and provides an update on the situation in aged care, and how boosters can assist in protecting the community against symptomatic infection and severe disease (5 mins).

By Prof Paul Van Buynder
Videos iconVideos
Image_Paul-Van-Buynder0

New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

By Prof Paul Van Buynder
Videos iconVideos

Discover

Healthed

CPD platform

Save 50% on all seminars. Hurry, sale ends Dec 31!

You're invited to attend the Women's & Children's Health Update 2026, Australia's most popular seminar for GPs and healthcare professionals. Secure your seat by midnight Dec 31 and save!

Register for $135
WCH26 - Carousel Ad - MWCH26 date
WCH26 - Carousel Ad - SWCH26 date
WCH26 - Carousel Ad - BWCH26 date
WCH26 - Carousel Ad - PWCH26 date
WCH26 - Carousel Ad - AWCH26 date